Synbody Biotechnology Inc. (SBI), a Farmington, Connecticut-based startup biotechnology company, has received $750k in funding from Connecticut Innovations‘ Seed Investment Fund.
In conjunction with the funding, Daniel Wagner, CI managing director of investments, will join SBI’s board of directors.
Led by president, chief executive officer and co-founder Paul Hallenbeck, Ph.D., the company advances a novel drug discovery platform that utilizes unstructured, synthetically produced peptides to generate “Synbodies” (synthetic antibodies). Its patent-pending technology, which has a broad range of potential therapeutic application areas including oncology, cardiovascular, central nervous system, diabetes and infectious disease, has been developed at Arizona State University (ASU) and supported with over $10m in funding to date.
SBI’s co-founders also include:
– Kevin Burroughs, Ph.D., vice president of research and development;
– Stephen Johnston, Ph.D., member of the scientific team; and
– Chris Diehnelt, Ph.D., member of the scientific team;
FinSMEs
22/03/2012